FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR
- The U.S. FDA has approved Casgevy, the country's first gene-editing treatment, for sickle cell disease patients aged 12 and older.
- Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR technology to edit genes and treat the disease.
- Analysts raise concerns about the high cost, complexity, and limited availability of the treatment.
Insights by Ground AI
Does this summary seem wrong?
162 Articles
162 Articles
All
Left
35
Center
86
Right
16
Coverage Details
Total News Sources162
Leaning Left35Leaning Right16Center86Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 26%
C 63%
12%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage